International Journal of Urology最新文献

{"title":"Editorial Comment for “Clinical manifestations of patients with interstitial cystitis and bladder pain syndrome using a patient registry in Japan”","authors":"Hisae Nishii MD, PhD","doi":"10.1111/iju.15627","DOIUrl":"10.1111/iju.15627","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 1","pages":"109-110"},"PeriodicalIF":1.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comorbidities in Japanese testicular cancer survivors: A multi-institutional, cross-sectional study","authors":"Juntaro Koyama,&nbsp;Shinichi Yamashita,&nbsp;Kenichi Kakimoto,&nbsp;Motohide Uemura,&nbsp;Takeshi Kishida,&nbsp;Koji Kawai,&nbsp;Terukazu Nakamura,&nbsp;Takayuki Goto,&nbsp;Takahiro Osawa,&nbsp;Kazuo Nishimura,&nbsp;Norio Nonomura,&nbsp;Hiroyuki Nishiyama,&nbsp;Takumi Shiraishi,&nbsp;Osamu Ukimura,&nbsp;Osamu Ogawa,&nbsp;Nobuo Shinohara,&nbsp;Yoshimi Suzukamo,&nbsp;Akihiro Ito,&nbsp;Yoichi Arai","doi":"10.1111/iju.15622","DOIUrl":"10.1111/iju.15622","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate comorbidities in Japanese testicular cancer (TC) survivors in a multi-institutional, cross-sectional study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study enrolled TC survivors who visited any of the eight high-volume institutions in Japan from 2018 to 2019. After obtaining informed consent, participants answered questionnaires about their comorbidities. We analyzed the impact of treatment on comorbidities rate in TC survivors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 509 TC survivors responded to the comorbidity questionnaires. Median age at the time of response was 43 years (IQR 35–51 years) and median follow-up period after treatment was 5.1 years (IQR 2.1–9.2 years). TC survivors were divided according to the number of cycles of chemotherapy into the following groups: None (<i>n</i> = 153); 1–2 cycles (<i>n</i> = 34); 3–4 cycles (<i>n</i> = 234); or ≥5 cycles (<i>n</i> = 88). The prevalence of kidney disease increased significantly with increasing number of cycles of chemotherapy (<i>p</i> &lt; 0.05). The relative risk of cardiovascular disease in the groups with three or more cycles was 2.6 compared to the group without chemotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The present study showed that the prevalence of kidney disease in TC survivors was increased with increasing number of cycles of chemotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 2","pages":"198-202"},"PeriodicalIF":1.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is seated voiding associated with lower urinary tract symptoms, health conditions, or marital status? Findings by age group from the 2023 Japan Community Health Survey","authors":"Noritoshi Sekido,&nbsp;Nobuhiro Haga,&nbsp;Kenji Omae,&nbsp;Yasue Kubota,&nbsp;Takahiko Mitsui,&nbsp;Naoya Masumori,&nbsp;Motoaki Saito,&nbsp;Ryuji Sakakibara,&nbsp;Mikako Yoshida,&nbsp;Satoru Takahashi","doi":"10.1111/iju.15624","DOIUrl":"10.1111/iju.15624","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Seated voiding may be an attempt to obviate voiding dysfunction, improve physical stability during voiding, and prevent messy bathroom contamination. Therefore, we hypothesized that seated voiders had a higher prevalence of lower urinary tract symptoms (LUTS), deteriorating health conditions, and a higher marriage rate than standing voiders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Of the participants from the 2023 Japan Community Health Survey conducted by the Japanese Continence Society, 2936 men (mean age: 53.6 years old) were divided into sitting and standing groups based on their posture when voiding at home. Characteristics of the two groups were compared, and factors associated with seated voiding stratified by age were investigated using multivariable logistic regression analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One-thousand six-hundred and sixty men (57%) voided in the sitting position at home, and the proportion of seated voiding decreased with age. On multivariable analysis, comorbidities other than benign prostatic hyperplasia were associated with the standing group aged 40–59, and storage symptoms were associated with the seated group aged 60 and older. Being married was significantly and consistently associated with seated voiding across all ages.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Approximately 60% of Japanese men void in the sitting position at home. There are certain differences in the associations of LUTS and health conditions with voiding position by age, while seated voiding is consistently associated with marital status throughout all ages, which implies that sanitation matters.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 2","pages":"204-211"},"PeriodicalIF":1.8,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iju.15624","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia","authors":"So Inamura,&nbsp;Yusuke Fukiage,&nbsp;Hisato Kobayashi,&nbsp;Manami Tsutsumiuchi,&nbsp;Masaya Seki,&nbsp;Minekatsu Taga,&nbsp;Masato Fukushima,&nbsp;Motohiro Kobayashi,&nbsp;Osamu Yokoyama,&nbsp;Naoki Terada","doi":"10.1111/iju.15612","DOIUrl":"10.1111/iju.15612","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>α-1 blockers and dutasteride are widely used as agents to treat benign prostatic hyperplasia (BPH); the impact of these drugs on prostatic inflammation is still unclear. Herein, we investigated the impact of α-1 blockers and dutasteride treatment of BPH in terms of the degree of prostatic inflammation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Tissue specimens were obtained from 143 BPH patients who were administered α-1 blockers up until their operation. Thirty-three of the patients had also been treated with dutasteride before the procedure. The degree of prostatic inflammation was quantified histologically by the ratio of high endothelial venule (HEV)-like vessels. We divided this retrospective cohort into α-1 blocker monotherapy and combination therapy (α-1 blockers + dutasteride) groups and evaluated clinical parameters of the two groups in relation to the degree of chronic prostatic inflammation. At the same time, we assessed factors exacerbating chronic prostatic inflammation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Comparison of the monotherapy and combination therapy groups showed no significant differences in the parameters of the urodynamic study or degree of chronic prostatic inflammation, whereas the IPSS total score, voiding subscore, nocturia, intermittency, weak stream, and straining were significantly lower in the combination than the monotherapy group. The duration of α-1 blockers administration was not correlated with the ratio of HEV-like vessels, while that of dutasteride was strongly correlated (correlation coefficient = 0.595; <i>p</i> &lt; 0.001). Multiple regression analysis demonstrated that the duration of dutasteride administration was a key factor exacerbating the degree of chronic prostatic inflammation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present study showed that despite their ameliorating effect on prostatic hyperplasia, dutasteride contributed significantly to chronic prostatic inflammation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 2","pages":"151-157"},"PeriodicalIF":1.8,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iju.15612","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the identity of Gerota fascia? Histological study with cadavers","authors":"Yasuyuki Kobayashi,&nbsp;Kohei Edamura,&nbsp;Takuya Sadahira,&nbsp;Yusuke Tominaga,&nbsp;Satoshi Katayama,&nbsp;Takehiro Iwata,&nbsp;Shingo Nishimura,&nbsp;Tomoko Kobayashi,&nbsp;Keita Sato,&nbsp;Takaaki Komiyama,&nbsp;Ryusuke Momota,&nbsp;Hideyo Ohuchi,&nbsp;Motoo Araki","doi":"10.1111/iju.15596","DOIUrl":"10.1111/iju.15596","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The advancement of laparoscopic surgery has allowed surgeons to see finer anatomical structures during surgery. As a result, several issues have arisen regarding Gerota fascia that cannot be explained by previous interpretations, such as its various forms observed during surgery. To address these issues, we histologically examined the structure of Gerota fascia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Specimens for study were prepared from kidneys with Gerota fascia from four cadavers, and the structure was studied histologically. Its thickness and collagen fiber area ratios were measured using ImageJ and compared to those of the epimysium of the rectus abdominis muscle.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Connective tissue that appeared to be Gerota fascia was observed in 26 specimens. Histologically, the basic structure of Gerota fascia was a sandwich-like structure with a thin layer of thick, long collagen fibers in the central layer, and small granular collagen fibers scattered at the edges. However, not all areas observed had a similar structure; eight specimens were composed only of small granular collagen fibers. The average thickness of the Gerota fascia was 466 μm, and the area ratio of collagen was 27.1%. In contrast, the epimysium was much thicker than Gerota fascia, and its collagen fibers were much thicker and denser.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Gerota fascia, unlike the epimysium, was a very thin and fragile layer of collagen fibers, and its structure was diverse. This explains why Gerota fascia was observed in various states during surgery. It is important for surgeons to understand the properties of Gerota fascia and to treat it appropriately.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 1","pages":"62-68"},"PeriodicalIF":1.8,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Comment to “Management of apalutamide-induced rash with focus on early peaks”","authors":"Sayuri Takahashi MD, PhD","doi":"10.1111/iju.15611","DOIUrl":"10.1111/iju.15611","url":null,"abstract":"&lt;p&gt;Apalutamide is one of the androgen receptor signaling inhibitor (ARSi) agents, and often prescribed for the patients diagnosed as high-risk prostate cancer or castration-resistant prostate cancer with androgen deprivation therapy (ADT). Urologists often see patients who develop skin rash during the apalutamide treatment. Incidences of skin rash were frequent in a phase 3 study, with 23.8–29.2% of patients, and was distinctly high in Japanese patients, with rates of 32.3–53.6%.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Alexander Pan et al. reported apalutamide-related dermatologic adverse events (dAEs) are frequent and can be managed with topical ± oral steroids.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; With expanded approval of apalutamide, dAE identification and management are essential.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Alison et al. recently stated the importance of preventing skin problems and managing them at the earliest state.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; They developed practical guidance for the management of apalutamide-related dAEs by grade.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The early identification of rash and subsequent intervention resulted in quicker resolution and continuation of the cancer treatment.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;The present study by Hashimoto et al. was performed to determine the effect of early interventional protocol (EIP) developed by them on the continuation of apalutamide treatment.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; In this EIP, a moisturizing lotion, oral antihistamines, fexofenadine 60 mg twice daily, and topical corticosteroid, clobetasol propionate ointment were prescribed at the start of apalutamide treatment.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Then, patients started to use the medicine when rashes appeared by their own assessment with a reduced dose of apalutamide. Patients were also explained to capture a photograph of the rash and contact the clinic. In case, patients had fever, pain, or rashes with erosions or blisters, they were instructed to discontinue the apalutamide and consult a dermatologist.&lt;/p&gt;&lt;p&gt;In this study, 37 patients treated with apalutamide were enrolled and 15 patients had skin rash (40.5%). Apalutamide was continued at a reduced dose in 12 patients and discontinued in 2 patients during rash treatment. Only one patient terminated apalutamide treatment and systemic corticosteroids were administered by a dermatologist.&lt;/p&gt;&lt;p&gt;The incidence rate was similar with previous studies, however, this study showed EIP could elevate the rate of apalutamide continuation at a reduced dose with skin-rash treatment. There may exist an issue of the insurance medical treatment when topical corticosteroid, clobetasol propionate ointment which are strong medicine are prescribed for patients without any symptoms. At busy outpatient clinics with a full of patients, it is sometimes hard to care patients when skin rashes appeared expeditiously. Therefore, the education to patients and prescription in advance by following this EIP seems to be reasonable and useful for both pat","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 1","pages":"117"},"PeriodicalIF":1.8,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the association between chronic prostatitis and the risk of herpes zoster in a cohort study in Taiwan","authors":"Shih-Wei Lai,&nbsp;Yu-Hung Kuo,&nbsp;Kuan-Fu Liao","doi":"10.1111/iju.15605","DOIUrl":"10.1111/iju.15605","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The aim of the cohort research was to study the association between chronic prostatitis and the probability of herpes zoster in Taiwan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using the National Health Insurance Research Database (NHIRD) of Taiwan, we selected male persons newly diagnosed with chronic prostatitis aged 20–84 years between 2013 and 2020. These male persons were then matched with a non-prostatitis group who did not have a diagnosis of prostatitis by using 1:1 propensity score matching on age and relevant comorbidities. All participants were observed either until a new diagnosis of herpes zoster was noted or until the completion of the study period in 2020. Cox proportional hazards regression analysis was employed to study the hazard ratio (HR) and 95% confidence interval (CI) for the risk of herpes zoster associated with chronic prostatitis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 69 239 participants with chronic prostatitis and 69 239 participants with non-prostatitis were included in the analysis. The incidence rate of herpes zoster was higher in participants with chronic prostatitis compared to the non-prostatitis group (8.03 per 1000 person-years for chronic prostatitis group versus 4.74 per 1000 person-years for non-prostatitis group, incidence rate ratio = 1.69, and 95%CI = 1.59–1.81). After adjusting for co-variables, participants with chronic prostatitis were found to have a higher risk of developing herpes zoster compared to the non-prostatitis group (adjusted HR = 1.69, 95%CI = 1.59–1.81, and <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This cohort research suggests that people with chronic prostatitis may have a greater risk of developing herpes zoster compared to the non-prostatitis group in Taiwan. Preventive strategies, such as the administration of the herpes zoster vaccine, might be beneficial in people with chronic prostatitis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 2","pages":"138-144"},"PeriodicalIF":1.8,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial comment on the Role of cytoreductive nephrectomy in the era of immune checkpoint inhibitors: A review of current evidence and ongoing trials","authors":"Yusuke Goto M.D., Ph.D.","doi":"10.1111/iju.15618","DOIUrl":"10.1111/iju.15618","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 1","pages":"14-15"},"PeriodicalIF":1.8,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial Comment on “Management of apalutamide-induced rash with focus on early peaks”","authors":"Koji Hatano M.D., Ph.D.","doi":"10.1111/iju.15606","DOIUrl":"10.1111/iju.15606","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 1","pages":"116"},"PeriodicalIF":1.8,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of apalutamide-induced rash with focus on early peaks","authors":"Kohei Hashimoto MD, PhD,&nbsp;Tetsuya Shindo MD, PhD,&nbsp;Sachiyo Nishida MD, PhD,&nbsp;Ko Kobayashi MD, PhD,&nbsp;Toshiaki Tanaka MD, PhD,&nbsp;Naoya Masumori MD, PhD","doi":"10.1111/iju.15587","DOIUrl":"10.1111/iju.15587","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 1","pages":"113-115"},"PeriodicalIF":1.8,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}